Mary Elizabeth Westerman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mary Elizabeth Westerman has a total of 273 co-authors. Here are the top co-authors by number of shared publications:
Vidit Sharma
Department of Urology, Mayo Clinic, Rochester, MN, USA
11 shared publicationsStephen A. Boorjian
Rochester, MN
10 shared publications- Vitaly Margulis
Department of Urology University of Texas Southwestern Medical Center Dallas TX USA
7 shared publications Laura-Maria Krabbe
Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, USA
6 shared publicationsR. Houston Thompson
Department of Urology, Mayo Clinic, Rochester, MN
6 shared publications- Robert Jeffrey Karnes
Department of Urology Mayo Clinic Rochester Minnesota USA
6 shared publications
Latest Publications
- 9 October 2026
- Published by Wolters Kluwer Health in Journal of Urology
Editorial Comment
- 1 July 2026
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 216 (1) , 43-44
Editorial Comment
- 1 July 2026
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 216 (1) , 43-44
Editorial Comment
- Top Cited PapersOpen Access
- 1 February 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (4) , 274-285
Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non–Muscle-Invasive Bladder Cancer
PURPOSE: To compare patient-reported and clinical outcomes between radical cystectomy (RC) and bladder-sparing therapy (BST) in patients with recurrent high-grade non–muscle-invasive bladder cancer (NMIBC). PATIENTS AND METHODS: This pragmatic, prospective observational cohort study was designed with patients, who selected and prioritized outcomes. Eligible adults were candidates for both RC or BST, had previous induction Bacillus Calmette-Guérin (BCG), and received their last treatment within 12 months. The primary outcome was the EORTC-QLQ-C30 physical function scale at 12 months. Secondary outcomes included other EORTC-QLQ-C30 scales, depression, anxiety, bladder cancer–specific quality of life (QOL), financial burden, and cancer-specific outcomes. Targeted maximum likelihood estimation (TMLE) was used to calculate average treatment effect (ATE) estimates between arms. Inverse probability weighted risk ratios (wRR) were calculated using quasi-Poisson regression. RESULTS: Of 570 participants (mean age 71.4 years; 21% female), 371 selected BST and 199 selected RC. Physical function was significantly worse in the RC arm at 3 months; by 9 months, there was no difference between arms, and at 12 months, physical function did not differ (ATE, 0.9; 95% CI, –0.6 to 2.4; P = .22). RC was associated with better emotional function, generic health-related QOL, and financial burden, and lower depression and anxiety, while BST was associated with better bowel and sexual health. Cancer-specific survival was 99% for BST versus 96% for RC (wRR, 0.99; 95% CI, 0.97 to 1.01). RC was associated with a higher risk of adverse events and serious adverse events, including a 90-day mortality rate of 2.5%. CONCLUSION: Most patient-prioritized outcomes were similar or better among participants who chose RC compared with BST. These findings support the continued role of RC in managing recurrent high-grade NMIBC.
- 1 February 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (4) , 274-285
Top Cited PapersOpen AccessTwelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non–Muscle-Invasive Bladder Cancer
PURPOSE: To compare patient-reported and clinical outcomes between radical cystectomy (RC) and bladder-sparing therapy (BST) in patients with recurrent high-grade non–muscle-invasive bladder cancer (NMIBC). PATIENTS AND METHODS: This pragmatic, prospective observational cohort study was designed with patients, who selected and prioritized outcomes. Eligible adults were candidates for both RC or BST, had previous induction Bacillus Calmette-Guérin (BCG), and received their last treatment within 12 months. The primary outcome was the EORTC-QLQ-C30 physical function scale at 12 months. Secondary outcomes included other EORTC-QLQ-C30 scales, depression, anxiety, bladder cancer–specific quality of life (QOL), financial burden, and cancer-specific outcomes. Targeted maximum likelihood estimation (TMLE) was used to calculate average treatment effect (ATE) estimates between arms. Inverse probability weighted risk ratios (wRR) were calculated using quasi-Poisson regression. RESULTS: Of 570 participants (mean age 71.4 years; 21% female), 371 selected BST and 199 selected RC. Physical function was significantly worse in the RC arm at 3 months; by 9 months, there was no difference between arms, and at 12 months, physical function did not differ (ATE, 0.9; 95% CI, –0.6 to 2.4; P = .22). RC was associated with better emotional function, generic health-related QOL, and financial burden, and lower depression and anxiety, while BST was associated with better bowel and sexual health. Cancer-specific survival was 99% for BST versus 96% for RC (wRR, 0.99; 95% CI, 0.97 to 1.01). RC was associated with a higher risk of adverse events and serious adverse events, including a 90-day mortality rate of 2.5%. CONCLUSION: Most patient-prioritized outcomes were similar or better among participants who chose RC compared with BST. These findings support the continued role of RC in managing recurrent high-grade NMIBC.
- 1 May 2025
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 213 (5) , 567
Editorial Comment
- 1 May 2025
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 213 (5) , 567
Editorial Comment
- 15 October 2024
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 213 (1) , 51
Editorial Comment
- 15 October 2024
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 213 (1) , 51
Editorial Comment
- Open Access
- 5 September 2024
- Published by Ochsner Journal in Ochsner Journal
- Vol. 24 (3) , 171-178
Simple and Epididymal-Sparing Orchiectomy for Surgical Castration in Stage IV Prostate Cancer
Background: Androgen deprivation therapy, the mainstay of treatment for patients with advanced prostate cancer, can be either medical or surgical. Surgery has cost benefits compared to medical treatment. In this study, we evaluated the use of simple and epididymal-sparing orchiectomy in 2 different practice settings for the treatment of metastatic prostate cancer. Methods: We reviewed patients who underwent surgical castration for metastatic prostate cancer between 2011 and 2022. The primary outcome was achieving castration-level total testosterone of P = 0.84) or surgical technique (P = 0.90). Conclusion: Simple or epididymal-sparing orchiectomy is safe and effective for surgical castration and is an alternative to medical androgen deprivation therapy for patients diagnosed with metastatic prostate cancer regardless of the practice demographics.
- 5 September 2024
- Published by Ochsner Journal in Ochsner Journal
- Vol. 24 (3) , 171-178
Open AccessSimple and Epididymal-Sparing Orchiectomy for Surgical Castration in Stage IV Prostate Cancer
Background: Androgen deprivation therapy, the mainstay of treatment for patients with advanced prostate cancer, can be either medical or surgical. Surgery has cost benefits compared to medical treatment. In this study, we evaluated the use of simple and epididymal-sparing orchiectomy in 2 different practice settings for the treatment of metastatic prostate cancer. Methods: We reviewed patients who underwent surgical castration for metastatic prostate cancer between 2011 and 2022. The primary outcome was achieving castration-level total testosterone of P = 0.84) or surgical technique (P = 0.90). Conclusion: Simple or epididymal-sparing orchiectomy is safe and effective for surgical castration and is an alternative to medical androgen deprivation therapy for patients diagnosed with metastatic prostate cancer regardless of the practice demographics.
- 1 September 2024
- Published by Wolters Kluwer Health in Urology Practice
- Vol. 11 (5) , 880-881
Editorial Commentary
- 1 September 2024
- Published by Wolters Kluwer Health in Urology Practice
- Vol. 11 (5) , 880-881
Editorial Commentary